Actualización de resultados demográficos y terapéuticos de pacientes con Leucemia Mieloide Aguda no promielocítica en el Hospital Clínico de la Pontificia Universidad Católica de Chile

• Autores: Nicolás Triantafilo, Mauricio Sarmiento, James Campbell, Patricio Rojas, María José García, Vicente Sandoval, Pablo Bertín, Mauricio Ocqueteau, María Concepciãn Risueño, Isabel Rodríguez, Mauricio Galleguillos
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 150, Nº. 5, 2022, págs. 643-649
• Idioma: español
• Títulos paralelos:
  • Acute myeloid leukemia. Analysis of 114 patients
• Enlaces
  • Texto completo
• Resumen

  • Background: Acute myeloid leukemia (AML) is the most common leukemia in adults. Aim: To Describe our population of patients with AML and report the outcomes of our treatments. Material and Methods: Review of electronic clinical records of 114 patients with AML with a median age of 57 years (59% men). Results: Seventeen percent of patients were classified as low risk, 38% as intermediate risk and 33% as high risk. Seventy-six percent of patients were treated with intensive chemotherapy. Five years overall survival according to cytogenetic risk was 59, 41, and 12% in low, intermediate, and high-risk patients, respectively. The outcomes were better in patients under 60 years. The median survival of patients treated with intensive chemotherapy aged less than 60 years and 60 years and above was 3.4 and 1 year, respectively. Conclusions: Our results are comparable to those reported in developed countries. Improving the survival of patients 60 years and older is our main challenge.